Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Supernus Pharmaceuticals Inc SUPN

Healthcare
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:SUPN)

Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference

GlobeNewswire 9 days ago

Supernus Announces Third Quarter 2024 Financial Results

GlobeNewswire November 4, 2024

Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024

GlobeNewswire October 31, 2024

Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results

GlobeNewswire October 21, 2024

Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder

GlobeNewswire October 17, 2024

Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder

GlobeNewswire October 10, 2024

Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree

GlobeNewswire September 24, 2024

Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit

GlobeNewswire September 19, 2024

Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference

GlobeNewswire August 28, 2024
View More News ››

Opinion & Analysis (NDAQ:SUPN)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:SUPN)

(SUPN) On The My Stocks Page

JUST IN: $SUPN (SUPN) On The My Stocks Page2024-09-11 17:52:00 ET Stock Traders Daily has produced this trading report using a...
whytestocks - September 11, 2024

Supernus Pharmaceuticals, Inc. (SUPN): Navigating Challenges

http://beyondspx.com/2024/08/01/supernus-pharmaceuticals-inc-supn-navigating-challenges-driving-growth-and-advancing-a-robust-pipeline/
MikeTester - August 1, 2024

SUPN Price Target Alert: $40.00. Issued by Jefferies

JUST IN: $SUPN SUPN Price Target Alert: $40.00. Issued by Jefferies2024-04-08 12:00:03 ET Irene Buhalo from Jefferies issued a price...
whytestocks - April 8, 2024

Supernus to Participate in the TD Cowen 44th Annual Healthca

BREAKING NEWS: $SUPN Supernus to Participate in the TD Cowen 44th Annual Healthcare ConferenceROCKVILLE, Md., Feb. 28, 2024 (GLOBE...
whytestocks - February 28, 2024

watching this one for

a possible purchase this spring,it's getting close to its decade low from my charts and it does have almost a billion dollars cash,so...
coolfooldumbguy - February 26, 2020
View more Bullboard ››

Visionstate Corp.

Visionstate Corp.

Visionstate Corp.is a growth-oriented company that invests in the research and development of the Internet of Things, big ...
View More »